The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
Glass House Brands Inc. GLASF
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States.
read at $11.81
Glass House Brands Inc. holds its Accumulation at $11.81.
- PHPhase · the trend structure carries the Accumulation label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 26 days |
| Price | $11.81 |
| Valuation | N/A trailing · 44.57 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.51 |
The opportunity · what the numbers say it is worth
Our framework reads FAIR VALUE — it trades above our $9.19 fair value estimate.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
| Revenue growth | -9.60% |
| Profit margin | -20.67% |
| Debt to equity | 42.29 |
| Analyst consensus | None · 2 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 10.0% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 2.6% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 0.0% of assets, under the 49% limit. Pass
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Cannabis Shops Still Deep in the Red
Picture a grower running its own stores and selling bulk flower to other retailers, yet still reporting revenue down 10 percent and a 21 percent loss margin. Glass House trades at 44.6 times forward earnings with return on equity at minus 20 percent, well above our fair value of 9.19 against the current 11.81 price. The ethical screen clears it, but the numbers show a business that has not yet turned consistent cash.
The two-analyst median target of 16 sits even higher, yet offers little comfort when growth is negative and the company remains unprofitable. A premium multiple on shrinking sales rarely ends well in a market this fragmented and heavily regulated.
Margins stay thin while competition and state rules keep shifting, so any rebound in volumes could vanish quickly. The current price leaves no margin of safety. Analysis, not advice.
| Forward P/E | 44.6x expensive — the price assumes strong growth ahead |
| Revenue growth | -9.6% revenue is shrinking |
| Profit margin | -20.7% currently unprofitable |
| Return on equity | -20.4% not currently earning a positive return on equity |
| Debt to equity | 0.42 minimal debt — a conservative balance sheet |
| Current ratio | 1.85 healthy short-term liquidity |
| Beta | 0.51 steadier than the market |
| Market cap | $1.0B |
| Employees | 357 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in GLASF's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
GLASF trades on OQX. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.35 | +36.9% | · | $1,369 | +36.9% |
| 2 months | $8.11 | +57.8% | · | $1,578 | +57.8% |
| 3 months | $7.61 | +68.2% | · | $1,682 | +68.2% |
| 6 months | $5.80 | +120.8% | · | $2,208 | +120.8% |
| 1 year | $5.40 | +137.0% | · | $2,370 | +137.0% |
| 2 years | $7.14 | +79.4% | · | $1,794 | +79.4% |
| 3 years | $4.15 | +208.7% | · | $3,087 | +208.7% |
| 5 years | $9.96 | +28.5% | · | $1,285 | +28.5% |
Historical returns from market close data. Past performance does not guarantee future results.